iShares Genomics Immunology and Healthcare ETF (IDNA)
NYSEARCA: IDNA · Real-Time Price · USD
29.42
-0.21 (-0.71%)
Apr 28, 2026, 4:00 PM EDT - Market closed
-0.71% (1D)
| Assets | $161.27M |
| Expense Ratio | 0.47% |
| PE Ratio | 14.67 |
| Shares Out | 5.45M |
| Dividend (ttm) | $0.31 |
| Dividend Yield | 1.05% |
| Ex-Dividend Date | Dec 16, 2025 |
| Payout Ratio | 15.27% |
| 1-Year Return | +44.96% |
| Volume | 54,353 |
| Open | 29.50 |
| Previous Close | 29.63 |
| Day's Range | 29.42 - 29.60 |
| 52-Week Low | 19.11 |
| 52-Week High | 31.41 |
| Beta | 1.03 |
| Holdings | 67 |
| Inception Date | Jun 11, 2019 |
About IDNA
Fund Home PageThe iShares Genomics Immunology and Healthcare ETF (IDNA) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund tracks a market-cap-selected and -weighted index of global stocks involved in genomics, immunology, and bioengineering. IDNA was launched on Jun 11, 2019 and is issued by BlackRock.
Asset Class Equity
Category Health
Stock Exchange NYSEARCA
Ticker Symbol IDNA
ETF Provider BlackRock
Index Tracked NYSE FactSet Global Genomics and Immuno Biopharma Index
Top 10 Holdings
46.12% of assets| Name | Symbol | Weight |
|---|---|---|
| Moderna, Inc. | MRNA | 6.46% |
| Revolution Medicines, Inc. | RVMD | 5.99% |
| Arcellx, Inc. | ACLX | 5.15% |
| Ipsen S.A. | IPN | 4.74% |
| Takeda Pharmaceutical Company Limited | 4502 | 4.15% |
| Bayer Aktiengesellschaft | BAYN | 4.09% |
| GSK plc | GSK | 3.99% |
| Merck & Co., Inc. | MRK | 3.96% |
| BioNTech SE | BNTX | 3.86% |
| Roche Holding AG | ROP | 3.73% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 16, 2025 | $0.15546 | Dec 19, 2025 |
| Jun 16, 2025 | $0.15291 | Jun 20, 2025 |
| Dec 17, 2024 | $0.11105 | Dec 20, 2024 |
| Jun 11, 2024 | $0.11144 | Jun 17, 2024 |
| Dec 20, 2023 | $0.16925 | Dec 27, 2023 |
| Jun 7, 2023 | $0.07077 | Jun 13, 2023 |
News
Best Biotech ETFs for Q2 2021
The best biotech ETFs for Q2 2021 are ARKG, IDNA, and XBI.
5 years ago - Investopedia
3 ETFs For More Moderna Bets
Shares of biotechnology company Moderna Inc (NASDAQ: MRNA) jumped 20% Monday on news that its mRNA-1273 coronavirus vaccine candidate is making positive progress.
Other symbols: CNCR
6 years ago - Benzinga